Platform

KCI’s DMPK (Drug Metabolism and Pharmacokinetics) platform focuses on providing comprehensive in vivo pharmacokinetic (PK) and biochemical analyses for drug discovery and development companies, helping clients to understand the absorption, distribution, metabolism, and excretion (ADME) properties of their drug candidates, to optimize their drug designs, and to accelerate the clinical development process. With advanced experimental technology, rich project experience and efficient data analysis capability, the platform has a significant advantage in the field of in vivo PK studies and biochemical analysis, providing customers with high-quality, high-translational-value preclinical data support.